髓系转录因子及活化信号基因突变预测慢性髓性白血病结局
研究对394例慢性髓性白血病(CML)样本(诊断时254例、随访中140例)行基于smMIP的NGS检测40个基因,检出突变者诊断时占22.4%、随访时占27.9%;诊断时携带AS/MTF基因突变者接受伊马替尼治疗后治疗失败风险更高(HR 2.53,95%CI 1.13-5.66,P=.0239),二代TKI治疗者该不良影响不明确。
要点
- 诊断时携带AS/MTF基因突变者伊马替尼治疗后治疗失败风险升高(HR 2.53)。
- AS/MTF基因突变在多因素分析中为分子学反应、无失败生存和进展风险的独立不良预后因素。
- 二代TKI治疗患者中该突变的不良预后影响不明确。
核心结论
- 使用smMIP-based NGS检测AS/MTF基因突变可帮助识别治疗失败和进展风险较高的CML患者,并可能有助于 upfront TKI选择。
研究设计与样本
- 研究纳入394例CML样本,包括诊断时采集的254例和随访中采集的140例。
- 采用基于单分子分子倒置探针(smMIP)的二代测序(NGS)检测40个基因的复发突变位点,检测限为0.2%。
主要发现
- 57例诊断样本(22.4%)中检出70个突变,39例随访样本(27.9%)中检出64个突变。
- 诊断时携带任何突变与TKI治疗后较差结局相关,尤其是AS/MTF基因突变。
- 诊断时携带AS/MTF基因突变并接受伊马替尼治疗的患者治疗失败风险更高(HR 2.53,95%CI 1.13-5.66,P=.0239)。
- 二代TKI治疗患者中该突变的不良预后影响不明确。
- 多因素分析证实AS/MTF基因突变为分子学反应、无失败生存和进展风险的独立不良预后因素,并观察到进展至晚期疾病和总生存更差风险增高的非显著趋势。
关键数值与推荐
- 诊断样本突变检出:57/254例(22.4%),共70个突变。
- 随访样本突变检出:39/140例(27.9%),共64个突变。
- 伊马替尼治疗且诊断时携带AS/MTF基因突变者治疗失败风险:HR 2.53(95%CI 1.13-5.66,P=.0239)。
临床怎么用
- 作者认为使用smMIP-based NGS检测AS/MTF基因突变可帮助识别治疗失败和进展风险较高的CML患者,并可能有助于 upfront TKI选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advancements in genomics are transforming the clinical management of chronic myeloid leukemia (CML) toward precision medicine. The impact of somatic mutations on treatment outcomes is still under debate. We studied the association of somatic mutations in epigenetic modifier genes and activated signaling/myeloid transcription factors (AS/MTFs) with disease progression and treatment failure in patients with CML after tyrosine kinase inhibitor (TKI) therapy. A total of 394 CML samples were sequenced, including 254 samples collected at initial diagnosis and 140 samples taken during follow-up. Single-molecule molecular inversion probe (smMIP)-based next-generation sequencing (NGS) was conducted targeting recurrently mutated loci in 40 genes, with a limit of detection of 0.2%. Seventy mutations were detected in 57 diagnostic samples (22.4%), whereas 64 mutations were detected in 39 of the follow-up samples (27.9%). Carrying any mutation at initial diagnosis was associated with worse outcomes after TKI therapy, particularly in AS/MTF genes. Patients having these mutations at initial diagnosis and treated with imatinib showed higher risks of treatment failure (hazard ratio, 2.53; 95% confidence interval, 1.13-5.66; P = .0239). The adverse prognostic impact of the mutations was not clear for patients treated with second-generation TKIs. The multivariate analysis affirmed that mutations in AS/MTF genes independently serve as adverse prognostic factors for molecular response, failure-free survival, and progression risk. Additionally, there was an observable nonsignificant trend indicating a heightened risk of progression to advanced disease and worse overall survival. In conclusion, mutations in the AS/MTF genes using smMIP-based NGS can help identify patients with a potential risk of both treatment failure and progression and may help upfront TKI selection.
引用
- Perusini MA, Žáčková D, Kim T, et al. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood Adv. 2024. PMID: 38447114. doi:10.1182/bloodadvances.2023012127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。